Industry News



Industry News
Global Trends
Events Calendar
Web Links

Web Gallery

Advertising  Info



DuPont Opens Integrated Knowledge Center In India

DuPont India, a subsidiary of US-based science-based products and services company DuPont, has opened its integrated knowledge centre - DuPont Knowledge Centre (DKC) - at Hyderabad to provide basic discovery research and applications development services.

The new R&D centre, which comes as DuPont's first plant biotech research centre outside the USA, houses a biotechnology lab, a materials research lab, an applications development lab, a global engineering design centre and greenhouse in the fifteen acres premises in the ICICI knowledge Park in Genome Valley, Hyderabad.

The company is investing Rs 130 crore to construct its first research and development centre in India with focus on basic research, product application development across all five of its business growth platforms, and other knowledge services for global and local markets, announced DuPont.

The DuPont Knowledge Centre brings together basic research, applications development, engineering design, bioinformatics, patent services and many regional support services. The new research centre, built on a 'One DuPont' concept, will focus on integrated science research - unique combination of biology, chemistry, materials science and engineering - to develop the company's application pipeline in India and other emerging markets.

"The DuPont Knowledge Centre is a critical component of our growth strategy and our investment in the DKC further demonstrates our commitment to India," said Balvinder S Kalsi, president and chief executive officer, DuPont India. The centre will enable to increase the 'speed to market' with products that come out of the R&D and innovations pipeline, not only for India but also for other growth regions, and help the company in its mission to become a billion dollar company in its mission to become a billion dollar company, he added.

"We will have under one roof the key science such as organic, inorganic, and polymer chemistry, biology, and materials science coupled with engineering to create unique and commercializable solutions," says Homi Bhedwar, director, Dupont Knowledge Centre.

The DKC, with strength of 180 staff, is expected to accommodate more than 300 scientists, engineers and other employees will eventually work out of the DKC once it is fully functional, working closely with more than 5,000 scientists of DuPont located around the world. The facility is designed in a manner that allows for future expansion, informed DuPont in an announcement.

The DKC is the sixth major DuPont R&D facility outside the United States. DuPont has more than 50 R&D facilities throughout the world with 20 in the United States and more than 30 in 11 other nations. In addition to the Central R&D at the DuPont Experimental Station at Wilmington, USA, other major DuPont R&D facilities are located in Shanghai, China; Utsunomiya, Japan; Hsinchu, Taiwan; Wuppertal, Germany and Meyrin, Switzerland.

The company invests an average of $1.3 billion annually on global research and development in a diverse range of technologies for many markets including agriculture, automotive, construction, electronics, chemicals and industrial materials.

(Ref : Chronicle Pharmabiz dated December 4, 2008)

Marck To Set Up Sterile Dosages Facility With Rs 800 Mn

The Ahmedabad-based Marck Biosciences Ltd, a leading manufacturer and marketer of sterile dosages pharma products, is all set to set up a new facility to consolidate its position in the growing sterile dosages pharma market. The company would make an investment of Rs 800 million over the next three years for this end. The proposed new facility would be used to manufacture a comprehensive range of formulations and injectables in glass vials, sterile ointments, mono-dose ophthalmics and an array of lens cleaning solutions for global markets.

"With a wider and deeper portfolio of sterile dosages products, we will be able to address a large share of the sterile dosage market with both our own brand and through contract manufacturing. Marck Biosciences is committed to consolidate its outsourcing business by leveraging its sterile dosages expertise. The company's formulation and development is geared to match the market expectations, offering new product range to frontrunners in the market. Our existing facility has five blow-fill-seal technology lines. Having established ourselves in BFS sterile dosages market, we have decided to add new technological capabilities to manufacture a diverse range of sterile dosages products under different therapeutic segments," said, Bhavesh Patel, MD, Marck Biosciences.

(Ref : Chronicle Pharmabiz dated August 28, 2008)

GE Healthcare To Invest $50-60 Mn In India In 3 Years

GE Healthcare is planning an investment of $50-$60 million in India over the next three years as part of the public-private partnership efforts in the country. The company will tap the outsourcing opportunities to offer its radiology technology at the healthcare facilities in 10 states. These will include tie-ups with both private and government hospitals. The company has currently inked pact at Madhya Pradesh and Gujarat. There will also be five more GE installations at the medical college hospitals in Gujarat.

According to V. Raja, president & CEO, GE Healthcare, South Asia, each centre will need at investment of around $3 million. The biggest challenge in this PPP initiative is the reach and provide the affordability. There is a huge scope for us to offer our expertise and this is the only way to ensure early detection of diseases, he added.

Under the PPP model, GE Healthcare will set up advanced diagnostic imaging facilities like Bright-Speed Computed Tomography and High Definition Magnetic Resonance systems in each centre. Additionally, GE Healthcare will facilitate operation of these centres by engaging, professional radiologists, technicians and staff. GE Healthcare will facilitate training of staff and students, after sales service and so on to ensure high uptime of these equipments.

The tripartite pact by GE Healthcare with the state Governments and the healthcare providers provide reasonable healthcare costs using advanced technology.

(Ref : Chronicle Pharmabiz dated October 2, 2008)

Other News

DCGI Discontinues WHO-GMP Certification
HCL Technologies To Offer Tech Services To Medical Device Cos
Commerce Ministry Extends DEPB Scheme Withdraws Reduction In DEPB Rates
Nirmed Invests Rs 3 Cr For Greenfield Project To Manufacture Wound Care Products





Back | Back To Top | Previous